Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
1.40 HKD
603.35 M HKD
5.96 B HKD
63.63 M
About SHANGHAI HENLIUS BIOTECH INC
Sector
CEO
Jun Zhu
Headquarters
Shanghai
Website
Founded
2010
ISIN
CNE100003N76
FIGI
BBG00Q3NTQ54
Shanghai Henlius Biotech, Inc. engages in the production and sale of monoclonal antibody (mAb) drugs and the provision of related consultation and technical services, and the transfer of its own technology. It operates through the Mainland China and Overseas geographical segments. The company was founded by Wei Dong Jiang and Shi Gao Liu in 2010 and is headquartered in Shanghai, China.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of 2696 is 23.90 HKD — it has increased by 0.21% in the past 24 hours. Watch SHANGHAI HENLIUS BIOTECH INC stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on HKEX exchange SHANGHAI HENLIUS BIOTECH INC stocks are traded under the ticker 2696.
2696 stock has risen by 9.13% compared to the previous week, the month change is a 17.73% rise, over the last year SHANGHAI HENLIUS BIOTECH INC has showed a 102.54% increase.
2696 reached its all-time high on Jul 16, 2020 with the price of 67.05 HKD, and its all-time low was 9.60 HKD and was reached on Oct 6, 2023. View more price dynamics on 2696 chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
2696 stock is 0.63% volatile and has beta coefficient of 0.26. Track SHANGHAI HENLIUS BIOTECH INC stock price on the chart and check out the list of the most volatile stocks — is SHANGHAI HENLIUS BIOTECH INC there?
Today SHANGHAI HENLIUS BIOTECH INC has the market capitalization of 12.99 B, it has decreased by −0.22% over the last week.
Yes, you can track SHANGHAI HENLIUS BIOTECH INC financials in yearly and quarterly reports right on TradingView.
SHANGHAI HENLIUS BIOTECH INC is going to release the next earnings report on Mar 31, 2025. Keep track of upcoming events with our Earnings Calendar.
2696 net income for the last half-year is 418.60 M HKD, while the previous report showed 330.62 M HKD of net income which accounts for 26.61% change. Track more SHANGHAI HENLIUS BIOTECH INC financial stats to get the full picture.
No, 2696 doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Dec 21, 2024, the company has 3.64 K employees. See our rating of the largest employees — is SHANGHAI HENLIUS BIOTECH INC on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. SHANGHAI HENLIUS BIOTECH INC EBITDA is 1.26 B HKD, and current EBITDA margin is 18.37%. See more stats in SHANGHAI HENLIUS BIOTECH INC financial statements.
Like other stocks, 2696 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade SHANGHAI HENLIUS BIOTECH INC stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So SHANGHAI HENLIUS BIOTECH INC technincal analysis shows the buy rating today, and its 1 week rating is strong buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating SHANGHAI HENLIUS BIOTECH INC stock shows the buy signal. See more of SHANGHAI HENLIUS BIOTECH INC technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.